Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2025
0mins
Source: NASDAQ.COM
Analyst Ratings Overview: Recent evaluations of Immunocore Holdings by 9 analysts show a mix of bullish and bearish sentiments, with an average 12-month price target of $71.78, indicating a slight decrease in expectations over the past month.
Company Financial Performance: Immunocore Holdings demonstrates strong financial metrics, including a 33.16% revenue growth rate, a net margin of 5.35%, and high returns on equity and assets, although it faces concerns due to a higher-than-average debt-to-equity ratio of 1.15.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
